Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido[6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease.
Qyuns Therapeutics Co. Ltd. has entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd. granting the latter the exclusive global rights to develop, manufacture and commercialize QX-031N.
Beijing Fuyuan Medicine Co. Ltd. has described compounds acting as monocarboxylate transporter 4 (MCT4) inhibitors reported to be useful for the treatment of cancer, asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.
CF Pharmtech Inc. raised HK$607.67 million (US$78.12 million) through the sale of 41.19 million H shares on the Hong Kong Stock Exchange (HKEX) Oct. 8. The proceeds will be used to advance the Suzhou, China-based drug developer’s portfolio of inhalation candidates for respiratory diseases.
CF Pharmtech Inc. raised HK$607.67 million (US$78.12 million) through the sale of 41.19 million H shares on the Hong Kong Stock Exchange (HKEX) Oct. 8. The proceeds will be used to advance the Suzhou, China-based drug developer’s portfolio of inhalation candidates for respiratory diseases.
Recently launched Irish startup Phyxiom Ltd. hopes that its digital health platform will transform the clinical outcomes for patients with asthma and chronic obstructive pulmonary disease. By providing clinicians with real-time insights into lung function and medication adherence, the platform improves diagnosis accuracy and treatment outcomes.
Cryofocus Medtech (Shanghai) Co. Ltd. received U.S. FDA breakthrough device designation on July 24 for its cryoablation system for asthma. The Chinese med-tech’s stock (HKEX:6922) rose near 20% over two consecutive days on the Hong Kong Stock Exchange with the news, increasing from HK$5.00 ($.64) July 23 to HK$5.98 nearing the close of trading on July 25.
Researchers from Lifordi Immunotherapeutics Inc. have developed a novel antibody-drug conjugate (ADC) called LFD-200 that aims to selectively deliver a potent glucocorticoid (GC) payload directly to immune cells. This strategy may potentially offer a new way to treat autoimmune and inflammatory conditions while minimizing systemic toxicity.
Deepcure Inc. has nominated DC-15442, an oral selective STAT6 inhibitor, as its second development candidate. DC-15442 is designed to replicate the safety and efficacy of dupilumab, while offering an oral alternative to regular subcutaneous injections.
